FIA
GANX icon

FNY Investment Advisers’s Gain Therapeutics GANX Stock Holding History

FNY Investment Advisers’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,000
Closed -$6K – 896
2025
Q4 		$6K Buy
+2,000
New +$5.34K ﹤0.01% 711

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

FNY Investment Advisers's GANX Position: Q1 2026 in Review

FNY Investment Advisers sold out of Gain Therapeutics (GANX) in Q1 2026, closing a stake of 2,000 shares — an estimated $6K sold.

FNY Investment Advisers first reported a position in GANX in Q4 2025 and held it in 1 quarter. The position peaked at $6K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • FNY Investment Advisers reported no remaining Gain Therapeutics position as of Q1 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 2,000 Gain Therapeutics shares in Q1 2026, an estimated $6K.
  • FNY Investment Advisers first reported a position in Gain Therapeutics in Q4 2025 and held it in 1 quarter.
  • FNY Investment Advisers's Gain Therapeutics position peaked at $6K in Q4 2025.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.